Skip to content
Open access

Cross-protection of wildtype and vaccine-derived chikungunya virus antibodies against chikungunya and Mayaro viruses in mice

Oct 2026 · npj Vaccines · 0 citations

TL;DR

This study assessed antibody-mediated protection following vaccination or natural infection by passively immunizing transiently immunocompromised mice with graded doses of pooled immune sera before challenge with two CHIKV genotypes or the related Mayaro virus (MAYV).

Abstract

The live-attenuated vaccine IXCHIQ against chikungunya virus (CHIKV) was approved in 2023, with its efficacy evaluated using human neutralizing antibody titers as surrogate effectiveness criterion. Previous in vivo studies assessed its efficacy at high CHIKV-specific antibody titers, whereas its efficacy and antibody-dependent enhancement (ADE) risks at suboptimal levels mimicking long-term immunity remain poorly characterized. Here, we assessed antibody-mediated protection following vaccination or natural infection by passively immunizing transiently immunocompromised mice with graded doses of pooled immune sera before challenge with two CHIKV genotypes or the related Mayaro virus (MAYV). Protection was evaluated using viral loads at 3 days post-infection and clinical parameters. Vaccine- and infection-induced antibodies conferred strong protection against both CHIKV genotypes, even at antibody concentrations nearing ELISA detection limits. In contrast, protection against MAYV required higher titers. We observed no ADE. Our findings align with previous studies supporting durable protection against CHIKV and partial cross-protection against MAYV.

Read PDF

Similar papers

Open access Sep 2026

Immunological Correlate of Protection by PHV02 Live, Attenuated Recombinant VSV Vaccine Against Nipah Virus Disease Using an Improved Neutralizing Antibody Method, with Considerations for Future Research

Establishing the immune correlate of protection for a vaccine could be the basis for regulatory approval. The immune correlate of PHV02, a clinical-stage recombinant vesicular stomatitis (rVSV) vaccine against Nipah virus (NiV) disease, was investigated in the African green monkey (AGM) model. Although a mechanistic im...

Thomas P. Monath, R. Nichols, W. Rida et al. · 1 citation
Open access Sep 2026

Combined Vaccination with Recombinant HVT-ND and Live Newcastle Disease Vaccines Accelerates Early Immunity, Limits Virus Shedding and Reduces Transmission

Background/Objectives: Effective control of Newcastle disease (ND) requires a reduction in virus shedding and transmission. While recombinant herpesvirus of turkey vectored Newcastle disease (rHVT-ND) vaccines induce strong systemic immunity, their ability to generate early mucosal immunity and limit transmission may n...

Edit Kovács, T. Tatár-Kis, B. Felföldi et al. · 0 citations
Open access Oct 2026

An adenovirus-based mucosal vaccine induces cross-neutralizing antibodies and protects against lethal H5N1 infection in ferrets

Second-generation VXA-H5–02 is a promising vaccine candidate capable of inducing systemic and mucosal immunity, offering broad protection against HPAI, and significantly reduced illness, viral burden, and shedding.

Becca A. Flitter, Ka-Yan Tam, Laura J. Showalter et al. · 0 citations
Open access Nov 2026

Persistence of Vaccinia Virus-Neutralizing Antibodies and Cross-Reaction Against Monkeypox Virus Decades After Smallpox Vaccination in an Italian Population

Background/Objectives: Routine smallpox vaccination ended after eradication, leaving uncertainty about the persistence of vaccinia virus (VACV)-neutralizing antibodies and their activity against the monkeypox virus (MPXV) responsible for the 2022 outbreak. We assessed both responses in an Italian serum-bank cohort. Met...

Riccardo De Santis, G. Grilli, G. Faggioni et al. · 0 citations
Open access Oct 2026

Evaluation of Andes virus vaccine-derived human antibody for protection in Syrian hamsters: a passive transfer study using phase 1 trial sera

Summary Background Andes virus (ANDV) causes severe hantavirus pulmonary syndrome and is uniquely capable of person-to-person transmission, with no licenced vaccines or therapeutics available. A Phase 1 trial (NCT03682107) demonstrated that an ANDV DNA vaccine targeting Gn/Gc envelope proteins elicits neutralising anti...

Jay W. Hooper, Sydney Lesko, Lucia M. Principe et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.